Summary
Sudden Cardiac Arrest (SCA) is a life-threating heart condition and one of the most common causes of death in developed countries claiming many lives globally. There are currently two different implantable technologies to prevent SCAs: 1) Transvenous Implantable Cardioverter-Defibrillators (T-ICDs), which are implanted with wires that snake through veins into the heart; and 2) Subcutaneous Implantable Cardioverter-Defibrillators (S-ICD), which also have generators and leads but avoiding leads within the heart. However this solutions pose many drawbacks such as major complications to the vascular system, replacement needs, aesthetical and comfort impacts, complex implantation procedures and cyber-security issues.
The ISSD introduces a new dimension in subcutaneous ICDs. It is a totally integrated device fully inserted subcutaneously, with no leads within the heart, thus remaining the vascular system untouched. It is a wireless rechargeable device, halving replacement rates when compared to current technologies and it is totally seamless and integrated, so no generators or leads are needed. This makes the device almost invisible and improves patients comfort. It is designed from a cyber-security point of view and can be implanted in a rapid outpatient procedure (20 min on average).
So far, we have invested €8M which have helped us to ensure its robustness and efficiency and move into the commercialisation stage. To further develop the ISSD, overcome market barriers and deploy it at a European and global level we are seeking via the SME Instrument Phase 2 grant. The proposed work in SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the ISSD and its market uptake.
The ISSD introduces a new dimension in subcutaneous ICDs. It is a totally integrated device fully inserted subcutaneously, with no leads within the heart, thus remaining the vascular system untouched. It is a wireless rechargeable device, halving replacement rates when compared to current technologies and it is totally seamless and integrated, so no generators or leads are needed. This makes the device almost invisible and improves patients comfort. It is designed from a cyber-security point of view and can be implanted in a rapid outpatient procedure (20 min on average).
So far, we have invested €8M which have helped us to ensure its robustness and efficiency and move into the commercialisation stage. To further develop the ISSD, overcome market barriers and deploy it at a European and global level we are seeking via the SME Instrument Phase 2 grant. The proposed work in SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the ISSD and its market uptake.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/823081 |
| Start date: | 01-07-2018 |
| End date: | 31-03-2021 |
| Total budget - Public funding: | 3 519 750,00 Euro - 2 463 825,00 Euro |
Cordis data
Original description
Sudden Cardiac Arrest (SCA) is a life-threating heart condition and one of the most common causes of death in developed countries claiming many lives globally. There are currently two different implantable technologies to prevent SCAs: 1) Transvenous Implantable Cardioverter-Defibrillators (T-ICDs), which are implanted with wires that snake through veins into the heart; and 2) Subcutaneous Implantable Cardioverter-Defibrillators (S-ICD), which also have generators and leads but avoiding leads within the heart. However this solutions pose many drawbacks such as major complications to the vascular system, replacement needs, aesthetical and comfort impacts, complex implantation procedures and cyber-security issues.The ISSD introduces a new dimension in subcutaneous ICDs. It is a totally integrated device fully inserted subcutaneously, with no leads within the heart, thus remaining the vascular system untouched. It is a wireless rechargeable device, halving replacement rates when compared to current technologies and it is totally seamless and integrated, so no generators or leads are needed. This makes the device almost invisible and improves patients comfort. It is designed from a cyber-security point of view and can be implanted in a rapid outpatient procedure (20 min on average).
So far, we have invested €8M which have helped us to ensure its robustness and efficiency and move into the commercialisation stage. To further develop the ISSD, overcome market barriers and deploy it at a European and global level we are seeking via the SME Instrument Phase 2 grant. The proposed work in SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the ISSD and its market uptake.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
